Financhill
Sell
49

RGEN Quote, Financials, Valuation and Earnings

Last price:
$144.81
Seasonality move :
20.07%
Day range:
$143.96 - $150.56
52-week range:
$113.50 - $211.13
Dividend yield:
0%
P/E ratio:
628.56x
P/S ratio:
12.82x
P/B ratio:
4.01x
Volume:
1.4M
Avg. volume:
680.9K
1-year change:
-19.66%
Market cap:
$8.1B
Revenue:
$632.4M
EPS (TTM):
-$0.31

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RGEN
Repligen
$153.3M $0.33 0.61% 10.79% $191.46
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
QDEL
QuidelOrtho
$643.5M $0.32 -5.35% 520.47% --
VTAK
Catheter Precision
$290K -$2.60 118.75% -11.57% --
WST
West Pharmaceutical Services
$709.6M $1.49 1.63% -5.76% $371.01
XTNT
Xtant Medical Holdings
$29.3M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RGEN
Repligen
$144.47 $191.46 $8.1B 628.56x $0.00 0% 12.82x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
QDEL
QuidelOrtho
$44.87 -- $3B -- $0.00 0% 1.07x
VTAK
Catheter Precision
$0.33 -- $2.6M 0.38x $0.00 0% 0.88x
WST
West Pharmaceutical Services
$331.40 $371.01 $24B 49.17x $0.21 0.24% 8.53x
XTNT
Xtant Medical Holdings
$0.36 -- $50M -- $0.00 0% 0.42x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RGEN
Repligen
20.55% 1.044 6.26% 8.43x
CATX
Perspective Therapeutics
-- -5.312 -- --
QDEL
QuidelOrtho
44.46% 0.917 83.19% 0.64x
VTAK
Catheter Precision
12% -11.532 128.21% 0.53x
WST
West Pharmaceutical Services
6.86% 0.654 0.93% 1.97x
XTNT
Xtant Medical Holdings
43.2% 1.226 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RGEN
Repligen
$77.5M -$7.8M -0.32% -0.41% 2.57% $42.2M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
QDEL
QuidelOrtho
$352.3M $51.8M -29.13% -47.52% 2.85% $71.4M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
WST
West Pharmaceutical Services
$264.7M $165.7M 16.89% 18.16% 22.12% $98.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Repligen vs. Competitors

  • Which has Higher Returns RGEN or CATX?

    Perspective Therapeutics has a net margin of -0.42% compared to Repligen's net margin of --. Repligen's return on equity of -0.41% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    50.03% -$0.01 $2.5B
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About RGEN or CATX?

    Repligen has a consensus price target of $191.46, signalling upside risk potential of 32.53%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Repligen, analysts believe Perspective Therapeutics is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    9 5 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is RGEN or CATX More Risky?

    Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock RGEN or CATX?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or CATX?

    Repligen quarterly revenues are $154.9M, which are larger than Perspective Therapeutics quarterly revenues of --. Repligen's net income of -$654K is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Repligen's price-to-earnings ratio is 628.56x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.82x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.82x 628.56x $154.9M -$654K
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns RGEN or QDEL?

    QuidelOrtho has a net margin of -0.42% compared to Repligen's net margin of -2.74%. Repligen's return on equity of -0.41% beat QuidelOrtho's return on equity of -47.52%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    50.03% -$0.01 $2.5B
    QDEL
    QuidelOrtho
    48.45% -$0.30 $5.7B
  • What do Analysts Say About RGEN or QDEL?

    Repligen has a consensus price target of $191.46, signalling upside risk potential of 32.53%. On the other hand QuidelOrtho has an analysts' consensus of -- which suggests that it could grow by 13.98%. Given that Repligen has higher upside potential than QuidelOrtho, analysts believe Repligen is more attractive than QuidelOrtho.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    9 5 0
    QDEL
    QuidelOrtho
    0 2 0
  • Is RGEN or QDEL More Risky?

    Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.107, suggesting its less volatile than the S&P 500 by 89.318%.

  • Which is a Better Dividend Stock RGEN or QDEL?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or QDEL?

    Repligen quarterly revenues are $154.9M, which are smaller than QuidelOrtho quarterly revenues of $727.1M. Repligen's net income of -$654K is higher than QuidelOrtho's net income of -$19.9M. Notably, Repligen's price-to-earnings ratio is 628.56x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.82x versus 1.07x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.82x 628.56x $154.9M -$654K
    QDEL
    QuidelOrtho
    1.07x -- $727.1M -$19.9M
  • Which has Higher Returns RGEN or VTAK?

    Catheter Precision has a net margin of -0.42% compared to Repligen's net margin of -4291.67%. Repligen's return on equity of -0.41% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    50.03% -$0.01 $2.5B
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About RGEN or VTAK?

    Repligen has a consensus price target of $191.46, signalling upside risk potential of 32.53%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than Repligen, analysts believe Catheter Precision is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    9 5 0
    VTAK
    Catheter Precision
    0 0 0
  • Is RGEN or VTAK More Risky?

    Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

  • Which is a Better Dividend Stock RGEN or VTAK?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or VTAK?

    Repligen quarterly revenues are $154.9M, which are larger than Catheter Precision quarterly revenues of $96K. Repligen's net income of -$654K is higher than Catheter Precision's net income of -$4.1M. Notably, Repligen's price-to-earnings ratio is 628.56x while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.82x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.82x 628.56x $154.9M -$654K
    VTAK
    Catheter Precision
    0.88x 0.38x $96K -$4.1M
  • Which has Higher Returns RGEN or WST?

    West Pharmaceutical Services has a net margin of -0.42% compared to Repligen's net margin of 18.21%. Repligen's return on equity of -0.41% beat West Pharmaceutical Services's return on equity of 18.16%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    50.03% -$0.01 $2.5B
    WST
    West Pharmaceutical Services
    35.44% $1.85 $3B
  • What do Analysts Say About RGEN or WST?

    Repligen has a consensus price target of $191.46, signalling upside risk potential of 32.53%. On the other hand West Pharmaceutical Services has an analysts' consensus of $371.01 which suggests that it could grow by 11.95%. Given that Repligen has higher upside potential than West Pharmaceutical Services, analysts believe Repligen is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    9 5 0
    WST
    West Pharmaceutical Services
    6 3 0
  • Is RGEN or WST More Risky?

    Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.671%.

  • Which is a Better Dividend Stock RGEN or WST?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.24% to investors and pays a quarterly dividend of $0.21 per share. Repligen pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 9.61% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RGEN or WST?

    Repligen quarterly revenues are $154.9M, which are smaller than West Pharmaceutical Services quarterly revenues of $746.9M. Repligen's net income of -$654K is lower than West Pharmaceutical Services's net income of $136M. Notably, Repligen's price-to-earnings ratio is 628.56x while West Pharmaceutical Services's PE ratio is 49.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.82x versus 8.53x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.82x 628.56x $154.9M -$654K
    WST
    West Pharmaceutical Services
    8.53x 49.17x $746.9M $136M
  • Which has Higher Returns RGEN or XTNT?

    Xtant Medical Holdings has a net margin of -0.42% compared to Repligen's net margin of -17.98%. Repligen's return on equity of -0.41% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    50.03% -$0.01 $2.5B
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About RGEN or XTNT?

    Repligen has a consensus price target of $191.46, signalling upside risk potential of 32.53%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than Repligen, analysts believe Xtant Medical Holdings is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    9 5 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is RGEN or XTNT More Risky?

    Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

  • Which is a Better Dividend Stock RGEN or XTNT?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or XTNT?

    Repligen quarterly revenues are $154.9M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Repligen's net income of -$654K is higher than Xtant Medical Holdings's net income of -$5M. Notably, Repligen's price-to-earnings ratio is 628.56x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.82x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.82x 628.56x $154.9M -$654K
    XTNT
    Xtant Medical Holdings
    0.42x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is down 0.48% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 3% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock